ArticleBreast cancer research : BCR2013

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Wenle Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.